Altimmune, Inc. — Director's Dealing 2010

Dec 10, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-12-08

Reporting Person: Reinhart Charles A. III (SVP, Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-12-08	Stock Options (right to buy)	$3.55	A	75000	Acquired	2020-12-08	Common Stock (75000)	Direct

Footnotes

F1: The options vest over a 4 year period with 25% each vesting on the first, second, third and fourth anniversaries of the grant
date.

F2: On December 8, 2010, the date such options were granted, the closing price of the Issuer's Common Stock on the NYSE Amex was
$3.55 per share.